Clinical Characteristics of Parkinsonism in HTLV‐1‐Associated Myelopathy
ABSTRACT Objective Human T‐lymphotropic virus type 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is the classic neurological manifestation of HTLV‐1 infection; however, this virus has also been associated with other neurological disorders. Concurrent parkinsonism is relatively rare and presents diagnostic challenges.
Mika Dozono+8 more
wiley +1 more source
In the context of the era of targeted therapy: evaluation of the survival benefits of different local treatment modalities for patients with 1-3 brain metastases from non-small cell lung cancer. [PDF]
Sun L+8 more
europepmc +1 more source
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad+8 more
wiley +1 more source
The adolescent brain and age-related behavioral manifestations
L. Spear
semanticscholar +1 more source
Croonian Lectures on Mind, Brain, and Spinal Cord, in Certain Morbid Conditions [PDF]
Charles Bland Radcliffe
openalex +1 more source
Understanding Mechanisms of Whole Brain and Regional Grey Matter Atrophy in Children With MOGAD
ABSTRACT Objective To investigate the mechanisms driving whole brain and regional grey matter (GM) volume changes along with their clinical correlates in paediatric myelin oligodendrocyte glycoprotein antibody (MOG‐Ab)–associated disease (MOGAD). Methods One‐hundred‐nine paediatric MOGAD patients from two UK centres underwent MRI at attack nadir and ...
Ermelinda De Meo+14 more
wiley +1 more source
Why did the human brain size evolve? A way forward. [PDF]
González-Forero M, Gómez-Robles A.
europepmc +1 more source
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji+9 more
wiley +1 more source
Accurate and real-time brain tumour detection and classification using optimized YOLOv5 architecture. [PDF]
Saranya M, Praveena R.
europepmc +1 more source